Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonmyeloablative Allo-HCT with Busulfan and Fludarabine
NCT00448201Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jan 2011
- Primary completion
- Jan 2011
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of busulfan, fludarabine, antithymocyte globulin rabbit in chronic lymphocytic leukemia (CLL), Prolymphocytic leukemia (PLL), Chronic Myeloid Leukemia (CML), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Jan 2011; status: completed.
02
Drugs
busulfanfludarabineantithymocyte globulin rabbit
03
Conditions
chronic lymphocytic leukemia (CLL)Prolymphocytic leukemia (PLL)Chronic Myeloid Leukemia (CML)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00448201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00448201.